Impact of baseline characteristics on the efficacy of once‐weekly subcutaneous semaglutide among participants with type 2 diabetes : A post hoc analysis of SUSTAIN China

Ähnliche Einträge

• Effect of semaglutide on primary prevention of diabetic kidney disease in people with type 2 diabetes: A post hoc analysis of the SUSTAIN 6 randomized controlled trial
  von: Jingyu Wang, et al.
  Veröffentlicht: (2024)
• Effect of semaglutide versus placebo on cardiorenal outcomes by prior cardiovascular disease and baseline body mass index: Pooled post hoc analysis of SUSTAIN 6 and PIONEER 6
  von: Jingmin Zhou, et al.
  Veröffentlicht: (2025)
• Efficacy and safety of once‐weekly semaglutide 2.4 mg for weight management in participants from China: A prespecified analysis of the STEP 7 randomized clinical trial
  von: Weijun Gu, et al.
  Veröffentlicht: (2025)
• Effectiveness and safety of once‐weekly subcutaneous semaglutide versus other glucose‐lowering agents in real‐world patients with type 2 diabetes: A retrospective, observational post‐marketing study
  von: Chenyang Shi, et al.
  Veröffentlicht: (2024)
• Efficacy and hypoglycaemia outcomes with once‐weekly insulin icodec versus once‐daily basal insulin in individuals with type 2 diabetes by kidney function: A post hoc participant‐level analysis of the ONWARDS 1–5 trials
  von: Peter Rossing, et al.
  Veröffentlicht: (2025)